Abstract
Anal cancer accounts for only 4% of all cancers of the lower alimentary tract. However, the incidence is rising – possibly due to the higher incidence of persons engaging in anal-receptive intercourse. Chemoradiotherapy has become the standard treatment for localized anal squamous cell cancer (except for very small tumors of the anal margin). Improvement in therapeutic techniques such as intensity-modulated radiation therapy reduces toxicity, improves compliance, and therefore translates into better oncologic outcomes. Patients who fail the initial chemoradiotherapy should be considered for abdominoperineal resection or palliative chemotherapy. Patients with metastatic anal cancer are treated with cisplatin-based chemotherapy with or without radiotherapy (or surgery) to control the primary tumor. Cetuximab-based treatment may be used in patients with metastatic anal cancer (KRAS wild type) after failure of cisplatin-based chemotherapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 ASCRS (American Society of Colon and Rectal Surgeons)
About this chapter
Cite this chapter
Samdani, T., Nash, G.M. (2019). Anal Cancer. In: Steele, S., Hull, T., Hyman, N., Maykel, J., Read, T., Whitlow, C. (eds) The ASCRS Manual of Colon and Rectal Surgery. Springer, Cham. https://doi.org/10.1007/978-3-030-01165-9_21
Download citation
DOI: https://doi.org/10.1007/978-3-030-01165-9_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-01164-2
Online ISBN: 978-3-030-01165-9
eBook Packages: MedicineMedicine (R0)